Demand from all corners of the globe for the safety and security of U.S. Treasury debt has acted to keep a lid on long-term interest rates, even as the Federal Reserve has raised short-term rates ...

Shares of Biogen Inc. BIIB slipped 1.79% to $116.49 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 2.36% to 5,158.20 and ...

Children in England with the rare muscle wasting disease spinal muscular atrophy (SMA) will get access to Biogen’s super-expensive new drug Spinraza after the manufacturer struck a deal with NHS ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

Biogen's new management is diversifying its product portfolio and optimizing costs, but faces significant risks from market share loss and generic competition. The fair valuation of Biogen shares ...

Biogen isn’t shy about aspirations to expand beyond neurology and further establish itself in immunology and rare diseases. Recent business development deals have focused on enhancing the ...

Biogen's research organization recently went through an overhaul that company leaders say should allow the Cambridge drugmaker to increase the number of molecules that get into the clinic, and ...

Jefferies analyst Michael Yee maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $130.00. The company’s shares closed last Friday at $115.17.

Eisai (ESAIY) and Biogen (BIIB) announced an update on the ongoing regulatory review of the Marketing Authorization Application, MAA, for lecanemab as a treatment for early AD by the European ...

With a market cap of $17.4 billion, Biogen Inc. (BIIB) is a global biotechnology leader focused on discovering, developing, and delivering innovative therapies for serious neurological and ...